NAV

TAS-102

Identification

Generic Name
TAS-102
DrugBank Accession Number
DB08937
Background

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

Type
Small Molecule
Groups
Investigational
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Not Available
CAS number
733030-01-8
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004 Sep;25(3):571-8. [Article]
  2. Link [Link]
PubChem Substance
347910389
Wikipedia
TAS-102

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentColorectal Cancer1
3Active Not RecruitingTreatmentColorectal Neoplasms1
3CompletedTreatmentColorectal Cancer2
3CompletedTreatmentRefractory Metastatic Gastric Cancer1
3RecruitingTreatmentColorectal Cancer1
3RecruitingTreatmentColorectal Neoplasms1
3WithdrawnTreatmentCarcinoma / Metastatic Colorectal Cancer (CRC)1
2Active Not RecruitingTreatmentAdvanced Bile Duct Carcinoma / Advanced Gallbladder Carcinoma / Refractory Bile Duct Carcinoma / Refractory Gallbladder Carcinoma / Stage III Distal Bile Duct Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage III Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIA Distal Bile Duct Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIB Distal Bile Duct Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v8 / Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Bile Duct Cancer AJCC v8 / Stage IVA Gallbladder Cancer AJCC v8 / Stage IVB Gallbladder Cancer AJCC v81
2Active Not RecruitingTreatmentAdvanced Colorectal Carcinoma / Metastatic Colon Adenocarcinoma / Metastatic Rectal Adenocarcinoma / Recurrent Colon Adenocarcinoma / Recurrent Colorectal Adenocarcinoma / Recurrent Rectal Adenocarcinoma / Stage III Colon Cancer AJCC v8 / Stage III Colorectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Colon Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Colon Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colon Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v8 / Unresectable Colon Adenocarcinoma / Unresectable Colorectal Carcinoma / Unresectable Rectal Adenocarcinoma1
2Active Not RecruitingTreatmentCholangiocarcinoma / Stage III Gallbladder Cancer AJCC V7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVB Gallbladder Cancer AJCC v71

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at March 07, 2014 17:52 / Updated at June 12, 2020 16:52